Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human Remove Human filter Veterinary Remove Veterinary filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

Summaries of opinion Remove Summaries of opinion filter Withdrawn applications Remove Withdrawn applications filter Maximum residue limits Remove Maximum residue limits filter Referrals Remove Referrals filter

Product number

Date of opinion

From:

To:

Referral name

Referral status

European Commission final decision (28) Apply European Commission final decision filter

Referral safety status

Yes (5) Apply Yes filter

Referral type

Article 20 procedures Remove Article 20 procedures filter Article 13 Remove Article 13 filter Article 29(4) referrals (116) Apply Article 29(4) referrals filter Article 31 referrals (115) Apply Article 31 referrals filter Article 30 referrals (95) Apply Article 30 referrals filter Article 33 (43) Apply Article 33 filter Article 35 (40) Apply Article 35 filter Article 6(12) referrals (prior to January 2010) (21) Apply Article 6(12) referrals (prior to January 2010) filter Article 34 (18) Apply Article 34 filter Article 107 procedures (prior to July 2012) (15) Apply Article 107 procedures (prior to July 2012) filter Article 29 paediatrics (9) Apply Article 29 paediatrics filter Article 36 referrals (prior to July 2012) (9) Apply Article 36 referrals (prior to July 2012) filter Article 107i procedures (8) Apply Article 107i procedures filter Article 13 referrals (6) Apply Article 13 referrals filter Article 6(13) referrals (prior to January 2010) (5) Apply Article 6(13) referrals (prior to January 2010) filter Article 78 (5) Apply Article 78 filter Articles 39 and 40 (4) Apply Articles 39 and 40 filter Article 5(11) referrals (prior to January 2010) (2) Apply Article 5(11) referrals (prior to January 2010) filter

Referral reference number

Referral decision making model

PRAC-CHMP-EC (18) Apply PRAC-CHMP-EC filter

Referral authorisation model

Centrally authorised product(s) (20) Apply Centrally authorised product(s) filter

Referral PRAC recommendation

No further action (1) Apply No further action filter Risk minimisation measures (12) Apply Risk minimisation measures filter Suspension (3) Apply Suspension filter Variation (2) Apply Variation filter

Referral procedure start date

From:

To:

Referral PRAC recommendation date

From:

To:

Decision date

From:

To:

Medicine type

Accelerated assessment (2) Apply Accelerated assessment filter Additional monitoring (12) Apply Additional monitoring filter Conditional approval (1) Apply Conditional approval filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

28 results

Remove all filtersRemove all filters

Medicine Maximum residue limits Remove Maximum residue limits filter Withdrawn applications Remove Withdrawn applications filter Summaries of opinion Remove Summaries of opinion filter Referrals Remove Referrals filter

Categories Veterinary Remove Veterinary filter Human Remove Human filter

Referral type Article 20 procedures Remove Article 20 procedures filter Article 13 Remove Article 13 filter

Sort by

List item

Referral: Picato

ingenol mebutate, associated names: Picato, Article 20 procedures
Status: European Commission final decision, opinion/position date: 30/04/2020, EC decision date: 06/07/2020, Last updated: 16/11/2020
List item

Referral: Yondelis

trabectedin, associated names: Yondelis, Article 20 procedures
Status: European Commission final decision, opinion/position date: 24/07/2020, EC decision date: 24/09/2020, Last updated: 09/10/2020
List item

Referral: Xeljanz

tofacitinib, associated names: Xeljanz, Article 20 procedures
Status: European Commission final decision, opinion/position date: 14/11/2019, EC decision date: 31/01/2020, Last updated: 06/03/2020
List item

Referral: Lemtrada

alemtuzumab, associated names: Lemtrada, Article 20 procedures
Status: European Commission final decision, opinion/position date: 14/11/2019, EC decision date: 16/01/2020, Last updated: 04/02/2020
List item

Referral: Lartruvo

olaratumab, associated names: Lartruvo, Article 20 procedures
Status: European Commission final decision, opinion/position date: 31/01/2019, EC decision date: 19/07/2019, Last updated: 22/08/2019
List item

Referral: Xofigo

radium Ra223 dichloride, associated names: Xofigo, Article 20 procedures
Status: European Commission final decision, opinion/position date: 26/07/2018, EC decision date: 28/09/2018, Last updated: 11/10/2018
List item

Referral: Esmya

ulipristal acetate, associated names: Esmya, Article 20 procedures
Status: European Commission final decision, opinion/position date: 31/05/2018, EC decision date: 26/07/2018, Last updated: 08/08/2018
List item

Referral: Zinbryta

daclizumab, associated names: Zinbryta, Article 20 procedures
Status: European Commission final decision, EC decision date: 27/03/2018, Last updated: 11/07/2018
List item

Referral: Seresto and its associated name Foresto

imidacloprid and flumethrin, associated names: Foresto, Article 13
Status: European Commission final decision, opinion/position date: 15/02/2018, EC decision date: 25/05/2018, Last updated: 10/07/2018
List item

Referral: Maci

matrix-applied characterised autologous cultured chondrocytes, associated names: Maci, Article 20 procedures
Status: European Commission final decision, opinion/position date: 25/09/2014, EC decision date: 19/11/2014, Last updated: 05/07/2018
List item

Referral: Zinbryta

daclizumab, associated names: Zinbryta, Article 20 procedures
Status: European Commission final decision, opinion/position date: 09/11/2017, EC decision date: 08/01/2018, Last updated: 12/01/2018
List item

Referral: SGLT2 inhibitors (previously canagliflozin)

canagliflozin, empagliflozin, dapagliflozin, canagliflozin / metformin, empagliflozin / metformin, dapagliflozin / metformin, associated names: Xigduo, Ebymect, Edistride, Synjardy, Forxiga, Jardiance, Vokanamet, Invokana, Article 20 procedures
Status: European Commission final decision, opinion/position date: 23/02/2017, EC decision date: 04/05/2017, Last updated: 08/05/2017
List item

Referral: Direct-acting antivirals indicated for treatment of hepatitis C (interferon-free)

daclatasvir / dasabuvir / sofosbuvir / ledipasvir / simeprevir / ombitasvir/paritaprevir / ritonavir, associated names: Sovaldi, Olysio, Viekirax, Harvoni, Exviera, Daklinza, Article 20 procedures
Status: European Commission final decision, opinion/position date: 15/12/2016, EC decision date: 23/02/2017, Last updated: 09/03/2017
List item

Referral: Zydelig

idelalisib, associated names: Zydelig, Article 20 procedures
Status: European Commission final decision, opinion/position date: 21/07/2016, EC decision date: 15/09/2016, Last updated: 03/10/2016
List item

Referral: SGLT2 inhibitors

canagliflozin, dapagliflozin,empagliflozin, associated names: Edistride, Ebymect, Xigduo, Vokanamet, Synjardy, Jardiance, Invokana, Forxiga, Article 20 procedures
Status: European Commission final decision, opinion/position date: 25/02/2016, EC decision date: 28/04/2016, Last updated: 18/05/2016
List item

Referral: Tysabri

natalizumab, associated names: Tysabri, Article 20 procedures
Status: European Commission final decision, opinion/position date: 25/02/2016, EC decision date: 25/04/2016, Last updated: 12/05/2016
List item

Referral: Human papillomavirus vaccines - Cervarix, Gardasil, Gardasil 9, Silgard

Cervarix : Bivalent HPV vaccine (types 16, 18) -Gardasil : quadrivalent HPV vaccine (types 6, 11, 16, 18)Gardasil 9 : 9-valent HPV vaccine (types 6, 11, 16, 18, 31, 33, 45, 52 and 58)Silgard : quadrivalent HPV vaccine (types 6, 11, 16, 18), associated names: Cervarix, Gardasil, Gardasil 9, Silgard, Article 20 procedures
Status: European Commission final decision, opinion/position date: 19/11/2015, EC decision date: 12/01/2016, Last updated: 20/01/2016
List item

Referral: Inductos

dibotermin alfa, associated names: Inductos, Article 20 procedures
Status: European Commission final decision, opinion/position date: 22/10/2015, EC decision date: 20/11/2015, Last updated: 07/12/2015
List item

Referral: Iclusig

ponatinib, Article 20 procedures
Status: European Commission final decision, opinion/position date: 23/10/2014, EC decision date: 15/01/2015, Last updated: 02/03/2015
List item

Referral: Corlentor and Procoralan

ivabradine, associated names: Corlentor and Procoralan, Article 20 procedures
Status: European Commission final decision, opinion/position date: 20/11/2014, EC decision date: 15/01/2015, Last updated: 16/02/2015
List item

Referral: Resflor solution injectable and associated names

florfenicol, flunixin, Article 13
Status: European Commission final decision, opinion/position date: 07/10/2014, EC decision date: 05/12/2014, Last updated: 09/01/2015
List item

Referral: Protelos and Osseor

strontium ranelate, Article 20 procedures
Status: European Commission final decision, opinion/position date: 20/02/2014, EC decision date: 15/04/2014, Last updated: 18/09/2014
List item

Referral: Vasotop P

ramipril, Article 13
Status: European Commission final decision, opinion/position date: 08/12/2009, EC decision date: 27/04/2010, Last updated: 14/08/2014
List item

Referral: Cobactan DC and its associated names

cefquinome, associated names: Cephaguard DC, Cobactan DC intramam Susp. Ad us. Vet, Cobactan DC suspension intramammaire, Article 13
Status: European Commission final decision, opinion/position date: 20/07/2006, EC decision date: 13/10/2006, Last updated: 12/08/2014
List item

Referral: Kogenate Bayer and Helixate NexGen

octocog alfa, Article 20 procedures
Status: European Commission final decision, opinion/position date: 19/12/2013, EC decision date: 20/02/2014, Last updated: 09/04/2014

Load more

28 results

Referral: Picato

Referral: Yondelis

Referral: Xeljanz

Referral: Lemtrada

Referral: Lartruvo

Referral: Xofigo

Referral: Esmya

Referral: Zinbryta

Referral: Seresto and its associated name Foresto

Referral: Maci

Referral: Zinbryta

Referral: SGLT2 inhibitors (previously canagliflozin)

Referral: Direct-acting antivirals indicated for treatment of hepatitis C (interferon-free)

Referral: Zydelig

Referral: SGLT2 inhibitors

Referral: Tysabri

Referral: Human papillomavirus vaccines - Cervarix, Gardasil, Gardasil 9, Silgard

Referral: Inductos

Referral: Iclusig

Referral: Corlentor and Procoralan

Referral: Resflor solution injectable and associated names

Referral: Protelos and Osseor

Referral: Vasotop P

Referral: Cobactan DC and its associated names

Referral: Kogenate Bayer and Helixate NexGen